|
|
|
| Clinical Effects of Transcatheter Trabeculectomy Combined with Intravitreal Injection of Ranibizumab for Neovascular Glaucoma and the Effects on Visual Acuity and Intraocular Pressure |
| GUO Bin, LI Jinjin |
| Fuyang People's Hospital, Anhui Fuyang 236000, China |
|
|
|
|
Abstract Objective: To study the effect of intravitreal injection of ranibizumab therapy in combination with trans-trabeculectomy in the treatment of neovascular glaucoma (NVG). Methods: By retrospective analysis, 70 NVG patients admitted from January 2020 to January 2022 were enrolled and divided into experimental group (35 cases) and control group (35 cases) according to different treatment methods. The experimental group received intravitreal injection of ranibizumab combined with trans-trabeculectomy, while the control group received trans-trabeculectomy. The incidence of IOP levels, visual acuity levels, ocular arterial hemodynamic parameters [coefficient of resistance (RI), peak systolic flow velocity (PSV), end-diastolic flow velocity (EDV)], serum interleukin-6 (IL-6) and overall efficiency after treatment, complications (ocular pain, anterior chamber blood accumulation, hypotension, corneal edema) were compared between the two groups before treatment and after 3 months of treatment. Results: Before treatment, there were no significant differences in intraocular pressure, visual acuity, RI, PSV, EDV and IL-6 levels between the two groups (P>0.05). After treatment, the levels of visual acuity, PSV and EDV in 2 groups were higher than before, while the levels of intraocular pressure, RI and IL-6 were lower than before, with statistical significance (P<0.05). The differences of visual acuity, PSV, EDV, Intraocular pressure, RI and IL-6 before and after treatment were statistically significant between the two groups (P<0.05). The total effective rate of the experimental group was higher than that of the control group, and the complication rate was lower, the difference was statistically significant (P<0.05). Conclusion: Intravitreal injection of ranibizumab combined with trans-trabeculectomy has significant effect in NVG treatment, which can effectively improve visual acuity, reduce intraocular pressure, improve arterial hemodynamics and IL-6 levels, and reduce complications.
|
|
|
|
|
|
[1] 季瑛,刘世龙,郭倩.玻璃体腔注射雷珠单抗联合复合式小梁切除术及全视网膜光凝治疗新生血管性青光眼的临床疗效[J].河北医学,2020,26(2):325-329.
[2] Wasaki K,Kojima S,Wajima R,et al.Comparing surgical outcomes in neovascular glaucoma between tube and trabeculectomy:a multicenter study[J].Ophthalmol Glaucoma,2022,15(34):483-488.
[3] 程丹平.雷珠单抗玻璃体腔内注射联合复合式小梁切除术对伴玻璃体积血新生血管性青光眼患者眼压及视力恢复的影响[J].哈尔滨医药,2021,41(6):88-89.
[4] 董晓飞,刘伟,刑悦.雷珠单抗联合Ahmed青光眼阀植入和小梁切除术治疗新生血管性青光眼的效果及安全性对比分析[J].广西医科大学学报,2020,37(12):2255-2259.
[5] 杨玉春.雷珠单抗注射液联合改良小梁切除术治疗新生血管性青光眼的疗效及对血液流变学的影响[J].血栓与止血学,2020,26(3):441-443.
[6] 中华医学会眼科学分会青光眼学组.中国新生血管性青光眼诊疗专家共识(2019年)[J].中华眼科杂志,2019,55(11):814-817.
[7] Urbonaviciute D,Buteikiene D,Januleviciene I.A review of neovascular glaucoma:etiology,pathogenesis,diagnosis,and treatment[J].Medicina,2022,58(12):1870.
[8] Tokumo K,Komatsu K,Yuasa Y,et al Treatment outcomes in the neovascular glaucoma tube versus trabeculectomy study[J].Graef Arch Clin Exp,2021,259(10):369-375.
[9] Palfi S M C,Seclaman E P,Barac R,et al.The role of Anti-VEGF agents in treatment of neovascular glaucoma[J].Rom Ophthalmol,2022,66(3):209-213.
[10] Xiao H G,Yu W W,Liang Y Yang,et alComparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma[J].Int Ophthalmol,2021,41(8):513-518.
[11] Elwehidy A S,Bayoumi N H L,Badawi A E,et al.Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma[J].Asia-Pac Ophthalmo,2019,8(4):239-243. |
|
|
|
2023, Vol. 29 
